We believe higher than expected effective tax rate (30.5%-31.5% as opposed to 27% in 2011) and operating expenses are responsible for the weak earnings guidance. The Zacks Consensus Estimate of $3.24 billion is well within the company’s guidance range.Įndo Pharma expects to end 2012 with adjusted earnings in the range of $5.00-$5.20.The guidance is much below the pre-earnings Zacks Consensus Estimate of $5.47.
The company expects revenues in the range of $3.15-$3.30 billion, well above 2011 levels. 2011 revenues edged past the Zacks Consensus Estimate of $2.71 billion.Īpart from disclosing financial results, Endo Pharma provided guidance for 2012. Revenues were within the guidance range of $2.72-$2.80 billion provided by the company. Revenues climbed 58.7% to $2.73 billion in 2011 driven by impressive performances across all segments at Endo Pharma. 2011 earnings surpassed the Zacks Consensus Estimate by 8 cents and were above the company’s guidance range of $4.55-$4.65 per share.
Endo pharma earnings full#
Costs related to the acquisition of American Medical Systems contributed to the increase.įor full year 2011, Endo Pharma earned $4.69 per share (up 35%). The remaining revenues came from services sales.Īdjusted operating expenses climbed 58.2% to $280 million. Revenues came from the acquisition of American Medical Systems, a leading pelvic-health devices provider, in June 2011. Revenues from devices sales came in at $142.0 million in the reported quarter. We remind investors that Qualitest Pharmaceuticals was purchased by Endo Pharma in 2010 for $1.2 billion in cash. Revenues from the segment were aided by the inclusion of results from Qualitest Pharmaceuticals (a generic company).
0 kommentar(er)
